[Targeted therapies in thoracic oncology].

Date publication

juin 2004

Journal

Revue des maladies respiratoires

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle

Tous les auteurs :
Quoix E, Beau-Faller M, Douillard JY, Milleron B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/15292845

Résumé

Better understanding of the alterations of cellular physiology during carcinogenesis has resulted in the development of new anticancer agents called biological targeted therapies. These therapies will probably complement the traditional treatments (surgery, radiotherapy and chemotherapy).

Mots clés

Alkyl and Aryl Transferases, antagonists & inhibitors, Cyclooxygenase 2, Farnesyltranstransferase, Humans, Isoenzymes, antagonists & inhibitors, Lung Neoplasms, drug therapy, Membrane Proteins, Metalloproteases, antagonists & inhibitors, Neovascularization, Pathologic, Prostaglandin-Endoperoxide Synthases, Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors, Signal Transduction

Référence

Rev Mal Respir. 2004 Jun;21(3 Pt 1):527-37